DKK 728.0
(2.82%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 164.35 Million DKK | 57.25% |
2022 | 99.03 Million DKK | 28.27% |
2021 | 77.2 Million DKK | 0.94% |
2020 | 76.48 Million DKK | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 48.73 Million DKK | 14.19% |
2024 Q2 | 48.73 Million DKK | 0.0% |
2023 Q1 | 38.95 Million DKK | 110.13% |
2023 FY | 155.72 Million DKK | 57.25% |
2023 Q3 | 39.87 Million DKK | 2.36% |
2023 Q2 | 38.95 Million DKK | 0.0% |
2023 Q4 | 42.68 Million DKK | 7.05% |
2022 Q2 | 26.54 Million DKK | 0.0% |
2022 Q1 | 26.54 Million DKK | 0.0% |
2022 FY | 99.03 Million DKK | 28.27% |
2022 Q3 | 18.53 Million DKK | -30.17% |
2022 Q4 | 18.53 Million DKK | 0.0% |
2021 FY | 77.2 Million DKK | 0.94% |
2020 FY | 76.48 Million DKK | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ALK-Abelló A/S | 2.36 Billion DKK | 93.062% |
Bavarian Nordic A/S | 3.02 Billion DKK | 94.565% |
Genmab A/S | 10.92 Billion DKK | 98.496% |
Novo Nordisk A/S | 93.92 Billion DKK | 99.825% |
Orphazyme A/S | 27.04 Thousand DKK | -607691.872% |
Pharma Equity Group A/S | 24.81 Million DKK | -562.367% |
Zealand Pharma A/S | 226.92 Million DKK | 27.575% |